Clinical Trial Update: Beta-Amyloid Imaging With [18F]NAV4694 PET in Predicting Progression to AD in Subjects MCI [Phase 2]

View source ↗

Summary

Phase 2 trial update on using the beta-amyloid PET tracer [18F]NAV4694 to predict progression from mild cognitive impairment to Alzheimer's disease; the study (…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Cognitive Impairment

Drugs mentioned

• [18F]NAV4694 (NAV4694)

Snippet

Sponsor: Navidea Biopharmaceuticals | Conditions: Mild Cognitive Impairment | Phase 2 | Status: TERMINATED | Results posted: 2024-08-14